Abstract:Abnormal activation of Hedgehog (Hh) signaling pathway mediates the genesis and progression of various tumors [1]. Currently, three drugs targeting the Hh signaling component Smoothened (Smo) have been marketed for the clinical treatment of basal cell tumors or acute myeloid leukemia. However, drug resistance is a common problem in those drugs, so the study of Smo inhibitors that can overcome drug resistance has important guiding significance for clinical adjuvant drugs. MTT assay, clone formation assay and EdU assay were used to detect the proliferation inhibitory activity of the drugs on tumor cells. The effect of B13 on cell cycle and apoptosis were detected by flow cytometry. An acute toxicity test was used to detect the toxicity of B13 in vivo, and xenograft tumor model was used to detect the efficacy of B13 in vivo. The binding of B13 to Smo was studied by BODIPY-cyclopamine competitive binding assay and molecular docking. The effect of B13 on the expression and localization of downstream target gene Gli1/2 of Smo was investigated by Western Blot and immunofluorescence assay. SmoD473H mutant cell line was constructed to study the effect of B13 against drug resistance. (1) B13 had the strongest inhibitory activity against colorectal cancer cells. (2) B13 can effectively inhibit the clone formation and EdU positive rate of colon cancer cells. (3) B13 can block the cell cycle in the G2/M phase and cell apoptosis. (4) B13 has low toxicity in vivo, and its efficacy in vivo is better than that of the Vismodegib. (5) Molecular docking and BODIPY-cyclopamine experiments showed that B13 could bind to Smo protein. (6) B13 can inhibit the protein expression of Gli1, the downstream of Smo, and inhibit its entry into the nucleus. (7) B13 could inhibit the expression of Gli1 in the HEK293 cells with SmoD473H, and the molecular docking results showed that B13 could bind SmoD473H protein. B13 with the best anti-tumor activity was screened out by MTT assay. In vitro, pharmacodynamics experiments showed that B13 could effectively inhibit the proliferation and metastasis of colorectal cancer cells, induce cell cycle arrest, and induce cell apoptosis. In vivo pharmacodynamics experiments showed that B13 was superior to Vismodegib in antitumor activity and had low toxicity in vivo. Mechanism studies have shown that B13 can bind Smo protein, inhibit the expression of downstream Gli1 and its entry into the nucleus. Notably, B13 overcomes resistance caused by SmoD473H mutations.

Supplemental Figures from Arl13b Promotes Gastric Tumorigenesis by Regulating Smo Trafficking and Activation of the Hedgehog Signaling Pathway

Supplemental Materials and Figure Legends from Arl13b Promotes Gastric Tumorigenesis by Regulating Smo Trafficking and Activation of the Hedgehog Signaling Pathway

Suppression of Growth and Migration by Blocking the Hedgehog Signaling Pathway in Gastric Cancer Cells

ARL13B Promotes Angiogenesis and Glioma Growth by Activating VEGFA-VEGFR2 Signaling

ANGPTL1 Attenuates Colorectal Cancer Metastasis by Up-Regulating Microrna-138

[Hedgehog Signaling Pathway Activates in Gastric Carcinoma and Promotes the Proliferation Through GLI1 in MKN28 Cell].

B13, a well-tolerated inhibitor of hedgehog pathway, exhibited potent anti-tumor effects against colorectal carcinoma in vitro and in vivo

Oncogenic function of the homeobox A13-long noncoding RNA HOTTIP-insulin growth factor-binding protein 3 axis in human gastric cancer

HSulf-1 Suppresses Cell Growth and Down-Regulates Hedgehog Signaling in Human Gastric Cancer Cells

Hedgehog Signaling Pathway Regulates Growth of Human Digestive Tract Tumor Cells

Autocrine Sonic Hedgehog Signaling Promotes Gastric Cancer Proliferation Through Induction Of Phospholipase C Gamma 1 And The Erk1/2 Pathway

HSulf-1 Inhibits Cell Proliferation and Invasion in Human Gastric Cancer.

Human ribosomal protein S13 promotes gastric cancer growth through down-regulating p27(Kip1).

Autocrine Sonic hedgehog signaling promotes gastric cancer proliferation through induction of phospholipase Cγ1 and the ERK1/2 pathway

Supplementary Figures 1 - 3 from HOXB7 Promotes Malignant Progression by Activating the TGFβ Signaling Pathway

Knockdown Of Hmex-3a By Small Rna Interference Suppresses Cell Proliferation And Migration In Human Gastric Cancer Cells

Aplasia Ras Homolog Member I is Downregulated in Gastric Cancer and Silencing Its Expression Promotes Cell Growth in Vitro.

HOXD13 Suppresses Prostate Cancer Metastasis and BMP4‐induced Epithelial‐mesenchymal Transition by Inhibiting SMAD1

Long Noncoding RNA SNHG12 Promotes Gastric Cancer Proliferation by Binding to HuR and Stabilizing YWHAZ Expression Through the AKT/GSK-3β Pathway

Hsa-Mir-376c-3p Regulates Gastric Tumor Growth Both in Vitro and in Vivo

Identification of a Novel Regulator for Smoothened Signaling in Human Cancers